ReviewHepatology international2017
Primary biliary cholangitis: a comprehensive overview.
Review in Hepatology international, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Epidemiology and clinical course of primary biliary cholangitis in the Asia-Pacific region: a systematic review and meta-analysis.Hepatology international · 2019Pooled it
- The effectiveness of combining ursodeoxycholic acid with vitamin D in treating patients with primary biliary cholangitis and its impact on hepatic fibrosis: a randomized trial.BMC gastroenterology · 2025Trial
- Real-world treatment patterns and clinical outcomes of patients with primary biliary cholangitis in the United States.Journal of comparative effectiveness research · 2026Article
- Lipidome remodeling in primary biliary cholangitis.Lipids in health and disease · 2026Review
- Mortality trends and demographic-geographic disparities of autoimmune liver diseases among U.S. adults aged ≥45 years, 1999-2023.Frontiers in immunology · 2026Article
- Vitamin DScientific reports · 2025Article
- miRNA-21, an Important Regulator of Autoimmune Diseases.Current molecular medicine · 2025Review
- Review
- Causal relationship between primary biliary cholangitis and inflammatory bowel disease: a Mendelian randomization study.Gastroenterology report · 2024Article
- Farnesoid X Receptor Agonists: A Promising Therapeutic Strategy for Gastrointestinal Diseases.Gastro hep advances · 2024Review
- The exposome and liver disease - how environmental factors affect liver health.Journal of hepatology · 2023Review
- Article
- The Role of Sex in Acute and Chronic Liver Damage.International journal of molecular sciences · 2022Review
- Autoantibodies Associated with Autoimmune Liver Diseases in a Healthy Population: Evaluation of a Commercial Immunoblot Test.Diagnostics (Basel, Switzerland) · 2022Article
- Selected transgenic murine models of human autoimmune liver diseases.Pharmacological reports : PR · 2022Review
- Identification of circulating microRNAs as potential biomarkers for hepatic necroinflammation in patients with autoimmune hepatitis.BMJ open gastroenterology · 2022Article
- The effect of serum IL-2 levels on the prognosis of primary biliary cholangitis-related liver failure and the preliminary exploration of its mechanism.Frontiers in immunology · 2022Article
- Can Antinuclear Antibodies Have a Pathogenic Role in Systemic Sclerosis?Frontiers in immunology · 2022Review
- The HVEM-BTLA Immune Checkpoint Restrains Murine Chronic Cholestatic Liver Injury by Regulating the Gut Microbiota.Frontiers in immunology · 2022Article
- Systemic Lupus Erythematosus Patients With Related Organic Damage Are at High Risk of Hypothyroidism.Frontiers in endocrinology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary biliary cholangitis (PBC) is an autoimmune liver disease characterized by biliary destruction, progressive cholestasis, and potentially liver cirrhosis. Patients develop a well-orchestrated immune reaction, both innate and adaptive, against mitochondrial antigens that specifically targets intrahepatic biliary cells. A puzzling feature of PBC is that the immune attack is predominantly organ specific, although the mitochondrial autoantigens are found in all nucleated cells. The disease results from a combination of genetic and environmental risk factors; however, the exact pathogenesis remains unclear. Serologically, PBC is characterized by presence of antimitochondrial antibodies, which are present in 90-95 % of patients and are often detectable years before clinical signs appear. Like other complex disorders, PBC is heterogeneous in its presentation, symptomatology, disease progression, and response to therapy. A significant number of patients develop end-stage liver disease and eventually require liver transplantation. Recent studies from large international cohorts have better identified prognostic factors, suggesting a change in patient management based on risk stratification. Therapeutic options are changing. In this review we discuss data on the autoimmune responses and treatment of the disease.
Indexed as
Identifiers
29164395What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.